This study represents the follow-up, age 6-8 years, of children recruited at birth into two
cohorts. The first cohort, the Mite Allergen Prevention Study (MAPS) was a double-blind,
randomized controlled trial of the use of house dust-mite immunotherapy in the primary
prevention of atopy and asthma. The Immune Tolerance in Early Childhood (ITEC) cohort is a
separate observational cohort following up infants at high risk of atopy and correlating
atopic disease development with epigenetic markers.